Presented by BioPharm Process Associates…

• Amylin Pharmaceuticals (AMLN) said that Chairman Joseph Cook and director James Wilson failed to win re-election at last week’s annual meeting. They lost their seats to nominees backed by Carl Icahn and Eastbourne Capital Management. [WSJ Health Blog]

• Clinical Data’s (CLDA) vilazodone met its primary endpoint in a late-stage trial for major depressive disorder without reducing sexual drive. CLDA shares soar, will seek approval by year’s end. [Bloomberg]

• Genzyme and Bayer complete their Campath (alemtuzumab) deal. [Pharmalive]

• Kamada has submitted a Biologics License Application (BLA) to the FDA for its lead clinical candidate, intravenous alpha-1 antitrypsin, for the treatment of Alpha-1 Antitrypsin Deficiency. [ClinicaSpace]

• Arbor Pharmaceuticals has launched ZINOTIC ES for the treatment of acute otitis externa. [PR Newswire]

• Medivation (MDVN) presents prostate cancer data at ASCO. [Yahoo!Finance]

• Merck says Gardasil works in women ages 24-45. [MSNBC]

• Finally, The Motley Fool adds its two cents on Cell Therapeutics (CTIC). [Motley Fool]

Anonymous Tip? Comments? Contact us at: hr@iguanabio.com

Related Posts